Researchers determined 2 aspects of Epstein-Barrvirus, levels of anti–Epstein-Barr virus nuclear antigen-1 antibodies and history of infectious mononucleosis, act together and independently to increase risk of multiple sclerosis, according to a study published in Frontiers in Neurology.
Researchers determined 2 aspects of Epstein-Barr virus (EBV), levels of anti—Epstein-Barr virus nuclear antigen–1 (anti-EBNA-1) antibodies and history of infectious mononucleosis (IM), act together and independently to increase risk of multiple sclerosis (MS), according to a study published in Frontiers in Neurology.
Researchers used data from 2 population-based case-control studies in Sweden to determine the extent to which the relationship between IM history and MS risk is influenced by high levels of anti-EBNA-1 antibodies and vice versa. Human leukocyte antigen (HLA) genes, which are associated with MS, were analyzed to determine and gauge MS development. HLA class 1 genes are also involved in controlling EBV, authors said.
In total, the study included 5316 cases and 5431 matched controls. Researchers compared subjects with different HLA alleles, EBNA-1, and IM status. Odds ratios (ORs) were calculated with 95% CIs. “Trend test for a dose-response relationship regarding anti-EBNA-1 antibody levels and risk of MS was performed by using a continuous variable for anti-EBNA-1 antibody levels in a logistic regression model,” researchers said.
The study yielded the following results:
In addition, researchers found that for subjects categorized based on EBNA-1 status and IM history, “each factor increased MS risk in the absence of the other; high anti-EBNA-1 antibody levels conferred a 3-fold increased risk of disease (adjusted OR, 3.1; 95% CI, 2.8-3.3), whereas IM history increased MS risk by 50% (adjusted OR, 1.5; 95% CI, 1.4-1.7).”
Results support the hypothesis that both aspects of EBV infection act synergistically to increase MS risk and are thus partly involved in the same biological pathways.
Reference
Hedström AK, Huang J, Michel A, et al. High Levels of Epstein—Barr virus nuclear antigen-1-specific antibodies and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk. Front Neurol. 2020;10(1368). doi:10.3389/fneur.2019.01368.
Serum Neurofilament Light Changes Not Always Apparent in Active RRMS, Study Finds
May 8th 2024A prospective study found evidence of serum neurofilament light (sNfL) level increases in patients affected by active forms of relapsing-remitting multiple sclerosis (RRMS); however, these findings were not significant enough to suggest sNfL measurements replace clinical or MRI monitoring of disease activity.
Read More
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Distinguishing Biomarkers Identified in MS Outcomes
March 19th 2024Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).
Read More
FDA Issues CRL for Glatiramer Acetate Depot for Relapsing Forms of MS
March 11th 2024The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.
Read More